ADHD In Japan Starting To Find An Easier Regulatory Path; Shire Advances Pipeline
This article was originally published in PharmAsia News
Shire recently initiated a Phase II/III study for Intuniv, and Vyvanse is not far behind. Currently only two products are approved for ADHD in Japan.
You may also be interested in...
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.
Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.
Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.